Articles From: Bill Gross fund outflows top all of Janus fixed-income money to BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014


By Silvia Ascarelli, MarketWatch NEW YORK (MarketWatch) -- The amount of money that investors have pulled from the flagship Pimco fund that Bill Gross has been managing is more than double the fixed-income money managed by his new employer.
Sign-up for Bill Gross fund outflows top all of Janus fixed-income money investment picks
By Philip van Doorn, MarketWatch Pimco co-founder Bill Gross made a splash Friday, leaving the company in a way that seemed designed to cause as much turmoil as possible.
Sign-up for Bill Gross is definitely the smartest guy in the room at Janus investment picks
2014/11/20
By Mark DeCambreSoros approached Gross about putting money with Janus: Reuters NEW YORK (MarketWatch) -- Bill Gross just got a $500-million vote of confidence from one of Wall Street's most recognizable investors.
Sign-up for Bill Gross just scored a huge vote of confidence at his new fund investment picks
2014/9/26
By Chuck Jaffe, MarketWatch The moment Bill Gross's move from PIMCO to Janus was announced Friday morning, fund investors had two questions: 1) Do I sell the funds he was running at PIMCO?
Sign-up for Bill Gross left Pimco, should you? investment picks
2014/10/28
By Ben Eisen, MarketWatch NEW YORK (MarketWatch) -- Less money, fewer problems.
Sign-up for Bill Gross likely took a big pay cut to join Janus investment picks
2014/9/26
By David Weidner, MarketWatch SAN FRANCISCO (MarketWatch) -- The "bond king" is taking a bailout.
Sign-up for Bill Gross takes a bailout from Janus investment picks
2014/11/20
By Kirsten Grind And Gregory Zuckerman Before Bill Gross was fully settled in at his new firm, Janus Capital Group Inc., he received an unlikely visit from the chief investment officer of famed investor George Soros's firm, according to a person familiar with the meeting.
Sign-up for Bill Gross to Manage $500 Million for Soros Fund Management investment picks
The Janus Unconstrained Bond Fund (JUCAX) , which is now managed by bond specialist Bill Gross, took in $66.4 million in new investor money during September, according to data released by Morningstar on Wednesday.
Sign-up for Bill Gross-managed Janus fund attracts $66.4 mln in new money investment picks
2014/12/8
By Kirsten Grind Janus Capital Group Inc. has rallied its sales force around Bill Gross, helping to push the assets in his new mutual fund past the $1 billion mark in November.
Sign-up for Bill Gross's New Janus Fund Rises to $1.2 Billion in Assets -- 2nd Update investment picks
2014/12/8
By Kirsten Grind Investors poured $770 million into Bill Gross's new mutual fund at Janus Capital Group Inc. in November, pushing the fund past $1 billion of assets under management, according to data released Monday morning by fund research firm Morningstar Inc. The pace of monthly inflows was the highest since Mr.
Sign-up for Bill Gross's New Janus Fund Rises to $1.2 Billion in Assets -- Update investment picks
2014/12/8
Investors poured $770 million into Bill Gross's new mutual fund at Janus Capital Group Inc. in November, pushing the fund past $1 billion of assets under management, according to data released Monday morning by fund research firm Morningstar Inc. The pace of monthly inflows was the highest since Mr.
Sign-up for Bill Gross's New Janus Fund Rises to $1.2 Billion in Assets in November investment picks
By Kirsten Grind Bill Gross isn't yet attracting investors in droves to his new home.
Sign-up for Bill Gross's new Janus fund took in $364 million in his first month investment picks
2014/9/16
Today, to support STEM in schools, Bill Nye “the Science Guy” unveils a new GEOSET recording studio for faculty, students and area teachers to create educational videos – science research, class projects, experiments and more – for educators around the world.
Sign-up for Bill Nye the Science Guy Unveils New Mediasite Studio investment picks
Seagate Technology plc (NASDAQ:STX), a world leader in storage solutions, today announced that Bill Swales joined the company on September 30 as Senior Vice President of Worldwide Sales for the Cloud Systems and Solutions group, reporting to Seagate President Jamie Lerner.
Sign-up for Bill Swales Joins Seagate as Senior Vice President of Worldwide Sales for Cloud Systems and Solutions Group investment picks
LONGMONT, Colo., Sept.
Sign-up for Bill Wuertz to Join Dot Hill as Senior Vice President of Products and Solutions investment picks
2014/11/19
By Hannah Karp Starting next week there will be new ways for artists to climb the Billboard 200 album chart: selling singles and racking up streams on Spotify, changes that could complicate the ways record labels time the release of big new albums with chart-topping potential.
Sign-up for Billboard 200 Chart to Include On-Demand Streaming in Rankings investment picks
2014/11/19
By Hannah Karp Starting next week there will be new ways for artists to climb the Billboard 200 album chart: selling singles and racking up streams on Spotify, changes that could complicate the ways record labels time the release of big new albums with chart-topping potential.
Sign-up for Billboard 200 Chart to Include On-Demand Streaming in Rankings -- Update investment picks
2014/12/5
ADVISORY, Dec.
Sign-up for BillerudKorsnas AB to Ring The Nasdaq Stock Market Closing Bell investment picks
2014/9/29
By Kirsten Grind, Gregory Zuckerman and Min Zeng Pacific Investment Management Co.
Sign-up for Billions fly out the door at Pimco investment picks
2014/10/31
Biloxi Marsh Lands Corporation (PINK SHEETS: BLMC) today announces its unaudited results for the third quarter of 2014 and first nine months of 2014 and provides update.
Sign-up for Biloxi Marsh Lands Corporation Announces Unaudited Results for the Third Quarter and First Nine Months of 2014 and Provides Update investment picks
2014/12/11
During its meeting held today the Board of Directors of Biloxi Marsh Lands Corporation (Pink Sheets: BLMC) declared a dividend of $.40 per outstanding share of common stock payable on Tuesday, December 30, 2014 to shareholders of record as of the close of business on Monday, December 22, 2014.
Sign-up for Biloxi Marsh Lands Corporation Declares Cash Dividend investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.
Sign-up for BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced the online availability of an abstract providing preliminary data from the Q3W arm of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC). Data included in the abstract were current as of the submission deadline on June 13, 2014 and updated data will be presented in a poster presentation on November 19, 2014 at the 26 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Sign-up for BIND Therapeutics Announces Availability of Abstract with Preliminary Data from Phase 2 Study of BIND-014 in Non-small Cell Lung Cancer investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced the appointment of Hagop Youssoufian, M.Sc., M.D., as Chief Medical Officer.
Sign-up for BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical Officer investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today presented positive results from its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC), demonstrating it has met the primary objective in the once every three weeks (Q3W) arm as measured by overall response rate (ORR). The data demonstrate that BIND-014 is well-tolerated with clinically meaningful anti-tumor activity at a lower dose than conventional docetaxel in patients with advanced or metastatic NSCLC.
Sign-up for BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today reported financial results and business highlights for the third quarter ended September 30, 2014.
Sign-up for BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the following healthcare conferences during November 2014: Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com .
Sign-up for BIND Therapeutics to Present at November Healthcare Conferences investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the Oppenheimer 25 th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 3:55 p.m. EST.
Sign-up for BIND Therapeutics to Present at Oppenheimer 25th Annual Healthcare Conference investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced it will report third quarter 2014 financial results on Thursday, November 6, 2014.
Sign-up for BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Bill Gross fund outflows top all of Janus fixed-income money to BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent